IP Library Granted Patent US 8,295,924
Granted Patent B2
US 8,295,924 · App. 13/009,999 · Granted Oct 23, 2012

Transdermal systems for the delivery of ionic agents directly to open wounds and surgically repaired incisions

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,295,924
App. No.
13/009,999
Granted
Oct 23, 2012
Kind
B2
Abstract

A transdermal system for the delivery of an anesthetic or other active therapeutic agent directly to a selected site of injured skin tissue by iontophoresis is disclosed, which utilizes a transdermal skin-worn patch including a donor electrode chamber containing a donor electrode and an amount of an active agent in a form suitable for transdermal delivery in electrical communication with the donor electrode and a return electrode. The patch also contains a source of electric current connected in a circuit with the donor and return electrode, a current regulating device is optionally provided in the circuit for controlling the electrical output of the patch and at least the donor electrode chamber includes a provision for absorbing a quantity of fluid associated with weepage from adjacent injured skin tissue.

Claims (24)

1. A transdermal system for the delivery of an anesthetic agent directly to a selected site of an open skin wound by iontophoresis comprising: a transdermal skin-worn patch that is configured to include when applied to an open skin wound:

(a) a donor electrode chamber containing a donor electrode and an amount of anesthetic agent in a form suitable for transdermal delivery in electrical communication with said donor electrode, and a return electrode; (b) a source of electric current connected in a circuit with said donor and return electrodes; (c) wherein said donor electrode chamber includes a provision for absorbing a quantity of fluid associated with weepage from adjacent injured skin tissue.

2. A transdermal system as in claim 1 further comprising an amount of anesthetic agent in said patch.

3. A transdermal system as in claim 1 wherein said anesthetic agent is selected from lidocaine, bupivicaine, ropivicaine and mepivicaine.

4. A transdermal system as in claim 2 wherein said anesthetic agent is selected from lidocaine, bupivicaine, ropivicaine and mepivicaine.

5. A transdermal system as in claim 1 having a delivery output to ≦0.15 mA/cm 2 to the skin of a patient.

6. A transdermal system as in claim 1 that delivers medication over a period of at least thirty minutes.

7. A transdermal system as in claim 1 wherein the circuit includes a current regulating device in said circuit for controlling the electrical output of said patch, and current is maintained at <0.1 mA/cm 2 .

8. A transdermal system as in claim 1 wherein said donor electrode chamber is one of fixed volume that incorporates an absorbent pad for containing said anesthetic agent that has additional capacity to absorb a quantity of weepage fluid.

9. A transdermal system as in claim 1 wherein said donor electrode chamber includes a pad for containing said anesthetic agent and includes an expansion chamber in communication therewith that includes an absorbent pad that provides additional capacity to absorb a quantity of weepage fluid.

10. A transdermal system as in claim 1 comprising an expanding donor electrode chamber is provided with an absorbent pad for containing said anesthetic agent, said pad having additional capacity to absorb a quantity of weepage fluid while expanding the volume of said donor electrode chamber.

11. A transdermal system as in claim 2 wherein said anesthetic agent is contained in a water-based solution.

12. A transdermal system as in claim 2 wherein said anesthetic agent is contained in the form of a gelled material.

13. A transdermal system as in claim 12 wherein said gel comprises hydroxypropylmethylcellulose (HPMC).

14. A transdermal system as in claim 1 wherein said provision for absorbing fluid includes an absorbent pad.

15. A transdermal system as in claim 14 wherein said absorbent pad comprises natural or synthetic fibrous material.

16. A transdermal system for the delivery of an ionic therapeutic agent directly to a selected site of an open skin wound by iontophoresis comprising: a transdermal skin-worn patch that is configured to include when applied to an open skin wound:

(a) a donor electrode chamber containing a donor electrode and an amount of therapeutic agent in a form suitable for transdermal delivery in electrical communication with said donor electrode, and a return electrode;

(b) a source of electric current connected in a circuit with said donor and return electrodes; and

(c) wherein said donor electrode chamber includes a provision for absorbing a quantity of fluid associate with weepage from adjacent injured skin tissue.

17. A transdermal system as in claim 16 wherein said ionic agent is selected from the group consisting of antimicrobial and anti-acne agents.

18. A transdermal system as in claim 16 wherein said ionic therapeutic agent is an anti-acne agent.

19. A method of administering an ionic therapeutic agent directly to a selected site of an open skin wound comprising:

causing a skin-worn patch as in claim 16 to be positioned over a selected skin site, the donor electrode chamber placed over the desired treatment area.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 30, 2016
From: TEIKOKU PHARMA USA
To: NUPATHE INC.
Reel/Frame 039587/0687 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 30, 2016
From: NUPATHE INC.
To: TEVA PHARMACEUTICALS INTERNATIONAL GMBH
Reel/Frame 039588/0073 →
MERGER Recorded Nov 22, 2011
From: TRAVANTI PHARMA INC.
To: TEIKOKU PHARMA USA, INC.
Reel/Frame 027265/0395 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INVENTORS GIVING OWNERSHIP PREVIOUSLY RECORDED ON REEL 025670 FRAME 0486. ASSIGNOR(S) HEREBY CONFIRMS THE REMOVAL OF INVENTOR WALTER L. SEMBROWICH AND ADDING THE CORRECT INVENTOR RUSSELL L. MORRIS. Recorded Nov 17, 2011
From: ANDERSON, CARTER R.; MORRIS, RUSSELL L.; COHEN, ROBERT
To: TRAVANTI PHARMA, INC.
Reel/Frame 027248/0576 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 20, 2011
From: ANDERSON, CARTER R.; SEMBROWICH, WALTER L.; COHEN, ROBERT
To: TRAVANTI PHARMA INC.
Reel/Frame 025670/0486 →